Publisher Correction: defining global priorities in hematopoietic transplantation and cellular therapy: a statement paper from the EBMT global committee - Report - MDSpire
Clinical Report: Correction to EBMT Global Priorities Statement
Overview
A correction to the EBMT Global Committee statement on worldwide priorities for hematopoietic transplantation and cellular therapy added wording to the Methods section concerning approval by the EBMT Board of Directors and compliance with relevant requirements. The supplied context does not specify the complete inserted wording; it notes that the original article has been corrected.
Background
Hematopoietic cell transplantation and cellular therapies are addressed in EBMT guidance and reports covering clinical practice and activity. The related 2022 overview describes EBMT recommendations on HCT indications across EBMT countries and centres, drawing on clinical trials, registry data, and expert opinion. The 2024 activity report records more than one million HCTs reported since 1990 and 20,000 CAR-T treatments in 2024. The correction concerns the Methods wording of a statement about worldwide priorities, rather than reporting new clinical outcomes.
Data Highlights
Item
Information in supplied source
Correction article
Bone Marrow Transplantation, DOI 10.1038/s41409-026-03008-7
Online publication date stated in article context
11 August 2026
Correction described
Wording added to paragraph four of the Methods section, including approval by the EBMT Board of Directors and compliance with relevant requirements
Related EBMT activity context
In 2024, 47,204 HCTs were reported in 43,791 patients across 688 centres in 53 nations; cumulative reported HCTs exceeded one million since 1990
Key Findings
The correction concerns the EBMT Global Committee statement on worldwide priorities for hematopoietic transplantation and cellular therapy.
The supplied article context dates online publication to 11 August 2026 and identifies DOI 10.1038/s41409-026-03008-7.
The correction added wording to paragraph four of the Methods section.
The added wording states that approval was granted by the EBMT Board of Directors and that procedures complied with relevant requirements; the complete wording is not provided.
The supplied context notes a stray fragment, “are approved by the releva,” but does not provide the full corrected passage.
Related EBMT context includes a 2022 overview of HCT indications and a 2024 activity report documenting 47,204 HCTs across 53 nations.
Clinical Implications
This correction clarifies governance and compliance wording in the Methods section; the supplied material does not report changes to clinical findings or recommendations. The complete corrected wording should be consulted in the journal article for precise interpretation.
Conclusion
The correction updates the Methods text to state that the EBMT Board of Directors granted approval and that relevant requirements were followed. No additional clinical results are described in the supplied correction context.
